Amgen To Present At The 37th Annual J.P. Morgan Healthcare Conference
THOUSAND OAKS, Calif., Jan. 3, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the 37th Annual J.P. Morgan Healthcare Conference at 8:30 a.m. PT on Tuesday, Jan. 8, 2019, in San Francisco. Robert A. Bradway, chairman and chief executive officer at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology fo...
Source: Amgen News Release - January 3, 2019 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Submits Supplemental Biologics License Application For Nplate ® (romiplostim)
Application Seeks to Include Adult Patients who Have had Immune Thrombocytopenia for 12 Months or Less
THOUSAND OAKS, Calif., Dec. 19, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Nplate® (romiplostim) to include the treatment of adult patients with immune thrombocytopenia (ITP) who have had ITP for 12 months or less and an insufficient response to corticosteroids, immunoglobulins or splenectomy.
"Patients living with ITP need more flexibility in their treatment options, and we believe...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Molecular Partners Announce Strategic Collaboration In Immuno-Oncology
Parties Will Jointly Develop MP0310, a Pre-clinical FAP x 4-1BB Multi-Specific DARPin® Molecule, in Combination with Amgen's Oncology Assets, Including BiTE® Molecules
Molecular Partners Retains Rights to Develop MP0310 in Combination With its Pipeline Products
THOUSAND OAKS, Calif. and ZURICH-SCHLIEREN, Switzerland, Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company pioneering the use of DARPin® therapeutics, today announced a collaboration and license agreement for the clinical development and commercialization of MP0310 (FAP x 4-1BB). MP03...
Source: Amgen News Release - December 19, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Engages Cambridge Biotech Community To Select 2018 LabCentral Golden Ticket Winners
Amgen Golden Tickets Provide Startup Companies With Free Lab Space to Further Advance Innovative Science and Technology
CAMBRIDGE, Mass., Dec. 18, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and LabCentral today announced that Kernal Biologics and PanTher Therapeutics have each won the Amgen Golden Ticket at LabCentral. The two Golden Ticket winners were chosen by an Amgen internal committee and live audience members at a "Quick Pitch" event hosted by Amgen at its Cambridge, Mass. facility on Dec. 11, 2018. Six finalists pitched their business plans to attendees where the audience members' votes served as input for the A...
Source: Amgen News Release - December 18, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Submits Biologics License Application for ABP 710 (Biosimilar Infliximab) To US Food And Drug Administration
Filing for ABP 710, a Biosimilar Candidate to Infliximab, Supported by Phase 3 Study in Patients With Moderate-to-Severe Rheumatoid Arthritis
THOUSAND OAKS, Calif., Dec. 17, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ABP 710, a biosimilar candidate to REMICADE® (infliximab).
"At Amgen, we have spent nearly four decades developing, manufacturing and producing transformative medicines. We're leveraging our deep expertise and heritage in biologics to produce a portfolio of biosimilars to serve pati...
Source: Amgen News Release - December 17, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
FDA Approves Nplate ® (Romiplostim) For Use In Pediatric Patients With Immune Thrombocytopenia
Application Granted Priority Review Designation
Approval Based on Results That Demonstrated Nplate Successfully Increased and Sustained Platelet Counts in Children Affected by Rare Blood Disorder THOUSAND OAKS, Calif., Dec. 14, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Nplate® (romiplostim) for the treatment of pediatric patients one year of age and older with immune thrombocytopenia (ITP) for at least six months who have had an insufficient response to corticosteroids, immunoglobuli...
Source: Amgen News Release - December 14, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Direct Relief Partner To Aid Cancer Patients In 18 Developing Countries
Amgen Donates $93 Million Worth of Cancer Medicines
THOUSAND OAKS, Calif. and SANTA BARBARA, Calif., Dec. 13, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Direct Relief today announced a joint initiative in which Direct Relief will distribute $93 million worth of Amgen donated cancer treatments and supportive care medicines. This donation will provide cancer patients in 18 developing countries access to Neulasta® (pegfilgrastim), NEUPOGEN® (filgrastim) and Vectibix® (panitumumab).
Patients will access the donated medicines through Direct Relief-partner hospitals and clinics in the following countries: Armenia, Ca...
Source: Amgen News Release - December 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
deCODE Genetics, An Amgen Subsidiary, And SomaLogic Announce Collaboration To Perform Large-Scale Protein Analysis Of Up To 40,000 Human Samples
Largest-ever Protein Measurement Study Enhances deCODE's Efforts in Basic Research, Drug Discovery and Novel Protein-based DiagnosticsREYKJAVIK, Iceland and BOULDER, Colo., Dec. 13, 2018 /PRNewswire/ -- deCODE genetics, an Amgen subsidiary, and SomaLogic, Inc. today announced a collaboration that brings together SomaLogic's expertise in human proteins with deCODE's expertise in human genetics. The collaboration combines deCODE's rich data sets with SomaLogic's leading protein measurement capabilities to enhance the understanding of how human disease and health are mediated through proteins to influence health outcomes."I a...
Source: Amgen News Release - December 13, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Magellan Rx Management Collaborate To Improve Patient Care For Chronic, Difficult-To-Treat Conditions
First Amgen-Pharmacy Benefit Manager Value-Based Agreement to Deliver Advanced Solutions for Osteoporosis and Migraine
THOUSAND OAKS, Calif., Dec. 11, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced a novel multi-year collaboration with Magellan Rx Management, the pharmacy benefit management division of Magellan Health, that will leverage each company's capabilities and resources to identify clinical gaps for some of the healthcare system's most difficult-to-treat diseases. Based on Amgen and Magellan's extensive expertise in complex areas of health and specialty populations, the initial projects will focus ...
Source: Amgen News Release - December 11, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And Lazarex Cancer Foundation Team Up To Allow More Diversity In Clinical Trials
Amgen Contributes $2 Million to Groundbreaking Program Providing Cancer Patients of all Backgrounds Access to U.S. Clinical Trials
THOUSAND OAKS, Calif. and SAN FRANCISCO, Dec. 10, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and the Lazarex Cancer Foundation, a non-profit organization focused on improving patient access to cancer clinical trials, today announced that they have teamed up to support more equitable access to clinical trials for cancer patients in the U.S. Through a corporate donation, Amgen has contributed $2 million to Lazarex's IMPACT (IMproving Patient Access to Cancer Clinical Trials) program, which is...
Source: Amgen News Release - December 10, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces 10 Percent Increase In 2019 First Quarter Dividend
THOUSAND OAKS, Calif., Dec. 7, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the first quarter of 2019. The dividend will be paid on March 8, 2019, to all stockholders of record as of the close of business on Feb. 15, 2019. This represents a 10 percent increase from that paid in each of the previous four quarters.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using...
Source: Amgen News Release - December 7, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen Announces First-In-Human Data Evaluating Investigational Novel BiTE ® Immunotherapies AMG 420 And AMG 330 At ASH 2018
Phase 1 Results of Amgen's BiTE® Platform in Heavily Pre-Treated Patients With Multiple Myeloma and Acute Myeloid Leukemia
FDA Grants Fast Track Designation for AMG 420
THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the first clinical results from studies evaluating investigational novel bispecific T cell engager (BiTE®) immunotherapies AMG 420 and AMG 330. In two separate Phase 1 dose escalation studies, AMG 420, which targets B-cell maturation antigen (BCMA), and AMG 330, which targets CD33, provided early evidence of tolerability and anti-tumor activity in patients with...
Source: Amgen News Release - December 4, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Present At The Citi Global Healthcare Conference
THOUSAND OAKS, Calif., Dec. 3, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Citi Global Healthcare Conference at 12:35 p.m. ET on Thursday, Dec. 6, 2018, in New York City. Elliott M. Levy, M.D., senior vice president of Global Development at Amgen, will present at the conference. Live audio of the presentation can be accessed from the Events Calendar on Amgen's website, www.amgen.com, under Investors. A replay of the webcast will also be available on Amgen's website for at least 90 days following the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering fro...
Source: Amgen News Release - December 3, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen And UCB Announce FDA Advisory Committee Meeting To Review EVENITY ™ (romosozumab) For The Treatment Of Osteoporosis In Postmenopausal Women At High Risk For Fracture
THOUSAND OAKS, Calif. and BRUSSELS, Nov. 30, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced the U.S. Food and Drug Administration (FDA) Bone, Reproductive and Urologic Drugs Advisory Committee (BRUDAC) will review data supporting the Biologics License Application (BLA) for EVENITYTM (romosozumab) for the treatment of osteoporosis in postmenopausal women at high risk for fracture at a meeting on Jan. 16, 2019.
"After a fracture, postmenopausal women with osteoporosis are five times more likely to fracture in the subsequent year, and these fractures can be life-changing. Yet these...
Source: Amgen News Release - November 30, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
Amgen To Webcast Investor Call At ASH 2018
THOUSAND OAKS, Calif., Nov. 28, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition on Monday, Dec. 3, 2018, at 8 p.m. PT. David M. Reese, M.D., executive vice president of Research and Development at Amgen, together with other members of Amgen's management team and a clinical investigator, will participate to discuss data presented at ASH and the Company's oncology program, including the bispecific T Cell engager (BiTE®) immuno-oncology platform.
Live audio of the investor call will be simultan...
Source: Amgen News Release - November 28, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news
